Our top pick for
Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure
Arena Pharmaceuticals Inc is a biotechnology business based in the US. Arena Pharmaceuticals shares (ARNA) are listed on the NASDAQ and all prices are listed in US Dollars. Arena Pharmaceuticals employs 363 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$60.35|
|52-week range||$45.50 - $90.19|
|50-day moving average||$60.40|
|200-day moving average||$61.85|
|Wall St. target price||$95.56|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-8.18|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-14)||-5.32%|
|1 month (2021-09-24)||0.45%|
|3 months (2021-07-23)||-7.58%|
|6 months (2021-04-23)||-9.82%|
|1 year (2020-10-23)||-25.81%|
|2 years (2019-10-24)||23.42%|
|3 years (2018-10-24)||71.40%|
|5 years (2016-10-24)||3,695.60%|
Valuing Arena Pharmaceuticals stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Arena Pharmaceuticals's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Arena Pharmaceuticals's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.46. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Arena Pharmaceuticals's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Arena Pharmaceuticals's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $549.8 million.
The EBITDA is a measure of a Arena Pharmaceuticals's overall financial performance and is widely used to measure a its profitability.
|Gross profit TTM||$-323,421,000|
|Return on assets TTM||-26.32%|
|Return on equity TTM||-43.74%|
|Market capitalisation||$3.7 billion|
TTM: trailing 12 months
There are currently 2.5 million Arena Pharmaceuticals shares held short by investors – that's known as Arena Pharmaceuticals's "short interest". This figure is 5.6% up from 2.3 million last month.
There are a few different ways that this level of interest in shorting Arena Pharmaceuticals shares can be evaluated.
Arena Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Arena Pharmaceuticals shares currently shorted divided by the average quantity of Arena Pharmaceuticals shares traded daily (recently around 499598.58585859). Arena Pharmaceuticals's SIR currently stands at 4.95. In other words for every 100,000 Arena Pharmaceuticals shares traded daily on the market, roughly 4950 shares are currently held short.
However Arena Pharmaceuticals's short interest can also be evaluated against the total number of Arena Pharmaceuticals shares, or, against the total number of tradable Arena Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Arena Pharmaceuticals's short interest could be expressed as 0.04% of the outstanding shares (for every 100,000 Arena Pharmaceuticals shares in existence, roughly 40 shares are currently held short) or 0.0452% of the tradable shares (for every 100,000 tradable Arena Pharmaceuticals shares, roughly 45 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Arena Pharmaceuticals.
Find out more about how you can short Arena Pharmaceuticals stock.
We're not expecting Arena Pharmaceuticals to pay a dividend over the next 12 months.
Arena Pharmaceuticals's shares were split on a 1:10 basis on 18 June 2017. So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Arena Pharmaceuticals shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for Arena Pharmaceuticals shares which in turn could have impacted Arena Pharmaceuticals's share price.
Over the last 12 months, Arena Pharmaceuticals's shares have ranged in value from as little as $45.5 up to $90.19. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Arena Pharmaceuticals's is 0.436. This would suggest that Arena Pharmaceuticals's shares are less volatile than average (for this exchange).
Arena Pharmaceuticals, Inc. , a biopharmaceutical company, focuses on providing novel medicines with pharmacology and pharmacokinetics to patients worldwide. Its investigational clinical programs include Etrasimod (APD334) that is in Phase III clinical trial for ulcerative colitis, Phase IIb/III clinical trial for Crohn's disease, Phase II clinical trial for alopecia areata, Phase III clinical trial for atopic dermatitis, and Phase IIb clinical trial for eosinophilic esophagitis; Olorinab (APD371), which is in Phase IIb clinical trial for the treatment of abdominal pain associated with irritable bowel syndrome; APD418 that is in Phase I clinical trial for acute heart failure; and Temanogrel for coronary microvascular obstruction is in Phase II clinical trial. It also develops ralinepag (APD811), which is in Phase III clinical trial for pulmonary arterial hypertension. The company has collaboration agreements with Second Genome, Inc. ; United Therapeutics Corporation; Everest Medicines Limited; Beacon Discovery; Boehringer Ingelheim International GmbH; Eisai Co. , Ltd.
Steps to owning and managing ProShares Bitcoin Strategy ETF units.
Everything we know about the The Real Good Food Company IPO, plus information on how to buy in.
Everything we know about the Lulu’s Fashion Lounge Holdings IPO, plus information on how to buy in.
Everything we know about the Allarity Therapeutics IPO, plus information on how to buy in.
Everything we know about the Jupiter Neurosciences IPO, plus information on how to buy in.
Everything we know about the Mainz Biomed IPO, plus information on how to buy in.
Everything we know about the Progressive Care IPO, plus information on how to buy in.
Everything we know about the Desert Peak Minerals IPO, plus information on how to buy in.
Everything we know about the Vaxxinity IPO, plus information on how to buy in.
Everything we know about the Entrada Therapeutics IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.